Payment overview · 2025
General Payments
$322.47
16 reported records · 4 companies
Healthcare provider profile · identity verified
Jackson Brooks Turner, MD
Allopathic & Osteopathic Physicians|Family Medicine · EDGEWATER, FL · NPI 1285155259
Verified facts
What the public records show
CMS Open Payments records show Jackson Brooks Turner, MD received $322.47 in general payments during 2025 across 16 reported records.
Boston Scientific Corporation accounted for 67.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $216.17 | 67.0% | 11 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $68.01 | 21.1% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $24.24 | 7.5% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $14.05 | 4.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $322.47 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $110.64 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $68.01 | 3 | 2025 |
Source payment records
|
|||||
| VersaCross Access Solution Normalized: versacross access solution |
Device | Boston Scientific Corporation | $48.33 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $24.24 | 1 | 2025 |
Source payment records
|
|||||
| FARAPULSE Normalized: farapulse |
Device | Boston Scientific Corporation | $18.70 | 1 | 2025 |
Source payment records
|
|||||
| Rhythmia Mapping System Normalized: rhythmia mapping system |
Device | Boston Scientific Corporation | $16.61 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $15.47 | 2 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $14.05 | 1 | 2025 |
Source payment records
|
|||||
| General - EP Normalized: general ep |
Device | Boston Scientific Corporation | $6.42 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 429 | 139 |
| Levothyroxine Sodium | Levothyroxine Sodium | 414 | 132 |
| Losartan Potassium | Losartan Potassium | 274 | 82 |
| Amlodipine Besylate | Amlodipine Besylate | 243 | 83 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 229 | 36 |
| Omeprazole | Omeprazole | 210 | 67 |
| Pantoprazole Sodium | Pantoprazole Sodium | 196 | 69 |
| Tramadol Hcl | Tramadol Hcl | 196 | 51 |
| Lisinopril | Lisinopril | 194 | 65 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 188 | 63 |
| Metoprolol Tartrate | Metoprolol Tartrate | 165 | 56 |
| Alprazolam | Alprazolam | 160 | 29 |
| Gabapentin | Gabapentin | 150 | 46 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 127 | 50 |
| Furosemide | Furosemide | 126 | 54 |
| Lorazepam | Lorazepam | 123 | 24 |
| Eliquis | Apixaban | 122 | 39 |
| Metformin Hcl | Metformin Hcl | 116 | 41 |
| Fluticasone Propionate | Fluticasone Propionate | 105 | 42 |
| Trazodone Hcl | Trazodone Hcl | 99 | 31 |
| Simvastatin | Simvastatin | 98 | 29 |
| Potassium Chloride | Potassium Chloride | 97 | 37 |
| Pregabalin | Pregabalin | 88 | 17 |
| Lovastatin | Lovastatin | 85 | 24 |
| Temazepam | Temazepam | 85 | 15 |
| Montelukast Sodium | Montelukast Sodium | 82 | 28 |
| Famotidine | Famotidine | 81 | 30 |
| Prednisone | Prednisone | 75 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 74 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 74 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 71 | 21 |
| Carvedilol | Carvedilol | 70 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 69 | 15 |
| Sertraline Hcl | Sertraline Hcl | 68 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 67 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 67 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 64 | 19 |
| Meloxicam | Meloxicam | 64 | 29 |
| Eszopiclone | Eszopiclone | 62 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 60 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 60 | 12 |
| Atenolol | Atenolol | 58 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 56 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 54 | 25 |
| Allopurinol | Allopurinol | 53 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 48 | 15 |
| Glimepiride | Glimepiride | 44 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 43 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 42 | 14 |
| Xarelto | Rivaroxaban | 42 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 40 | 12 |
| Telmisartan | Telmisartan | 39 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 37 | 13 |
| Bupropion Xl | Bupropion Hcl | 37 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 37 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 35 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 35 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Fluconazole | Fluconazole | 34 | 15 |
| Azithromycin | Azithromycin | 33 | 30 |
| Ondansetron Odt | Ondansetron | 33 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 33 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | 11 |
| Mupirocin | Mupirocin | 32 | 17 |
| Clonidine Hcl | Clonidine Hcl | 30 | suppressed |
| Levofloxacin | Levofloxacin | 29 | 25 |
| Methocarbamol | Methocarbamol | 29 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 28 | suppressed |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | suppressed |
| Spironolactone | Spironolactone | 28 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 27 | suppressed |
| Clonazepam | Clonazepam | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 22 |
| Ibuprofen | Ibuprofen | 25 | suppressed |
| Valsartan | Valsartan | 25 | 13 |
| Verapamil Er | Verapamil Hcl | 25 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | 13 |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Lidocaine | Lidocaine | 23 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 21 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Primidone | Primidone | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 18 |
| Metformin Hcl Er | Metformin Hcl | 19 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 19 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Novolin N Flexpen | Insulin Nph Human Isophane | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Carbamazepine | Carbamazepine | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 16 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 16 | suppressed |
| Bumetanide | Bumetanide | 15 | 11 |
| Celecoxib | Celecoxib | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 14 |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Humira Pen | Adalimumab | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $322.47 · 16 records | Boston Scientific Corporation | CONTRAVE, Cologuard Collection Kit, FARAPULSE, General - EP, Rhythmia Mapping System, SHINGRIX, VersaCross Access Solution, WATCHMAN Access System, WATCHMAN FLX | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error